Clovis Oncology Inc (CLVS)

NASDAQ
3.200
-0.140(-4.19%)
After Hours
3.260
+0.060(+1.875%)
- Real-time Data
  • Volume:
    2,879,840
  • Bid/Ask:
    3.260/3.300
  • Day's Range:
    3.135 - 3.330

CLVS Overview

Prev. Close
3.34
Day's Range
3.135-3.33
Revenue
156.09M
Open
3.32
52 wk Range
3.04-11.09
EPS
-2.83
Volume
2,879,840
Market Cap
415.93M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,022,830
P/E Ratio
-
Beta
1.65
1-Year Change
-32.77%
Shares Outstanding
129,979,097
Next Earnings Date
Feb 23, 2022
What is your sentiment on Clovis Oncology Inc?
or
Market is currently closed. Voting is open during market hours.

Clovis Oncology Inc Company Profile

Employees
429

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell
  • Bull trap creating
    0
    • bottom is at 3.000?
      0
      • Let's hope so...
        0
      • not hope, but technicals. slightly above 3
        0
      • I TOLD YOU SO
        0
    • bulls doing down right awful here, action opens up 3.64 now...
      0
      • Any new news?
        0
        • had a shot at 5.54 a few days ago but bulls blew it. 4.05 now in play...
          0
          • buy more.this is our chance. dun miss it
            0
            • taking off
              1
              • It must be a private equity fund's play, just like the gamestop. it needs power from everybody who wants to save the justice. They need more education.Let's participate the war again
                0
                • hope it will be break $4.94
                  0
                  • spod out
                    0
                    • buy at dip will be $6 very soon
                      0
                      • 4.0 entry
                        0
                        • why down
                          0
                          • julia julia julia common I am tired of reading your posts always asking why down? Learn to trade!
                            0
                        • https://www.reddit.com/r/MicrocapStocksRun/comments/ox27pr/clvs_the_curious_case_of_clovis_oncology/?utm_source=share&utm_medium=web2x&context=3
                          0
                          • undervalue at least to $9 then$11 will see
                            0
                            • Why it is going down ? I don't see any sense now. What is your opinion for long term ? ( 1,2,3 years)
                              1
                              • I think we should pay close attention to ev finance company IDEANOMICS INC IDEX. Current price at $2.86 Solid future what are the prospects of a short squeeze there?
                                0
                                • 😤
                                  0
                                  • Digital Brands Group dopo aver recuperato il 15 % di perdita in giornata , fa + 20 % in after
                                    0
                                    • first price targe 9 soon
                                      0
                                      • what are we looking at here? price target?
                                        0
                                        • $12
                                          0
                                      • good day
                                        0
                                        • Hello Julia. Finally 🙏
                                          0
                                      • will go up
                                        1
                                        • 4.80 target?
                                          3
                                          • $7.4
                                            1
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.